Emerging Trends to Drive Neurogenetic Testing Market Growth at 13.5% CAGR Through 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Neurogenetic Testing Market Size Growth Forecast: What to Expect by 2025?
Recently, there has been a swift development in the neurogenetic testing market size. The market is set to expand from $0.61 billion in 2024 to $0.7 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 13.9%. Factors contributing to this growth, during the historical phase, include a rise in the number of neurological disorder cases, an escalation in life science research, an increase in Parkinson's disease prevalence, a surge in cancer diagnoses, and enhanced awareness among healthcare providers.

How Will the Neurogenetic Testing Market Size Evolve and Grow by 2029?
The market size for neurogenetic testing is projected to experience a swift expansion in the coming years, escalating to a worth of $1.16 billion by 2029, and growing at a compounded annual rate of 13.5%. Factors contributing to this growth during the projected period include the wider use in personalized medicine, an uptick in chronic illnesses, an expanding number of hospitals and diagnostic labs, along with an increased demand for early detection of diseases. Key trends anticipated within the forecast period encompass technological evolution, increased uptake of non-invasive testing procedures, introduction of new products, strategic partnerships, and the emergence of innovative biomarkers for neurological disorders.

View the full report here:
https://www.thebusinessresearchcompany.com/report/neurogenetic-testing-global-market-report

What Drivers Are Propelling the Growth of Neurogenetic Testing Market Forward?
The escalating incidence of disorders affecting the nervous system is anticipated to boost the expansion of the neurogenetic testing market. Neurogenetic testing plays a crucial role in the diagnosis, approach of treatment, and management of neurological disorders. It grants individualized information concerning genetic risk factors, influences therapeutic strategies, and enables individuals and their families to make knowledgeable decisions concerning their medical care, leading to an improvement in patient care and outcomes. For instance, the European Brain Council, a non-profit organization based in Belgium, reported in April 2022 that there were over 600 neurological diseases and approximately 300 psychiatric conditions impairing millions worldwide, with 65 million suffering from epilepsy. In Europe, it's estimated that over 10.5 million have dementia, with this figure likely to surge to 18.7 million by 2050. Hence, the increasing occurrence of neurological disorders is projected to stimulate the growth of the neurogenetic testing market. The neurogenetic testing market also gets a boost from the accelerating prevalence of cancer. Cancer, a disease characterized by the rampant division and destruction of body tissue by abnormal cells, has seen a surge due to factors like the obesity outbreak, inherited gene irregularities, certain viruses such as hepatitis B, C and Epstein-Barr, and human papillomavirus (HPV). Neurogenetic testing is important for cancer management as it enables the selection of the most appropriate treatment strategy. It aids in gauging prognoses, identifying high-risk patients, and tailoring care to each patient's genetic profile and family history. As per the American Society of Clinical Oncology, a US-based professional organization, around 20 million new cancer diagnoses were made in 2022, and it's estimated that by 2050, there will be 35 million new cases, contributing to 9.7 million fatalities. Therefore, the escalating incidence of cancer is predicted to stimulate the growth of the neurogenetic testing market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16131&type=smp

Which Emerging Trends Are Transforming the Neurogenetic Testing Market in 2025?
Prime firms in the neurogenetic testing market are advancing new products such as whole-genome sequencing with an aim to augment the precision and extend the range of genetic analysis. This way, they plan to offer more thorough and customized testing options for neurological disorders. Whole-genome sequencing (WGS) is a comprehensive method for genetic testing that involves reading the full DNA sequence of an individual's genome. Nucleus Genomics, a company based in the US which specializes in genetic analysis, is an example of this trend. In March 2024, they introduced a product for DNA analysis. This platform provides individuals with comprehensive insights into their genetic susceptibilities, allowing them to make informed choices regarding their health and well-being. Equipped with top-tier technology and specialized genetic counseling services, Nucleus Genomics is poised to transform the genetic testing industry by making whole-genome sequencing accessible to individuals and catalyzing a paradigm shift in genomic medicine.

What Are the Key Segments in the Neurogenetic Testing Market?
The neurogenetic testing market covered in this report is segmented -

1) By Type: Microarray Analysis, Whole-Exome Sequencing (WES), Multiplex Ligation Dependent Probe Amplification (MLPA), Polymerase Chain Reaction (PCR) Tests, Other Types
2) By Disease: Rare Genetic Disorder, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntington's Disease, Fragile X Syndrome, Other Diseases
3) By End-Users: Hospitals, Specialty Clinics, Research Institutes, Diagnostics Laboratories

Subsegments:
1) By Microarray Analysis: Comparative Genomic Hybridization (CGH) Microarray, Single Nucleotide Polymorphism (SNP) Microarray, Gene Expression Microarray
2) By Whole-Exome Sequencing (WES): Targeted Exome Sequencing, Clinical Exome Sequencing, Research-Grade Exome Sequencing
3) By Multiplex Ligation Dependent Probe Amplification (MLPA): MLPA For Copy Number Variation, MLPA For Methylation Analysis, MLPA For Specific Disease Detection
4) By Polymerase Chain Reaction (PCR) Tests: Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR (dPCR)
5) By Other Types: Next-Generation Sequencing (NGS), Southern Blotting, Fluorescence In Situ Hybridization (FISH), Sanger Sequencing

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=16131&type=smp

Who Are the Key Players Shaping the Neurogenetic Testing Market's Competitive Landscape?
Major companies operating in the neurogenetic testing market are Thermo Fisher Scientific Inc., Mayo Clinic, Roche Diagnostics Corporation, Laboratory Corporation, Quest Diagnostics Incorporated, Eurofins Scientific Inc., Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corporation, Myriad Genetics Inc., BioReference Laboratories Inc., Connecticut Children's, Invitae Corp., Ambry Genetics Corporation, Fulgent Genetics Inc., Blueprint Genetics Inc., GeneDx LLC, Pacific Biosciences of California Inc., MedGenome Labs, CENTOGENE, Baylor Genetics, Victorian Clinical Genetics Services

What Geographic Markets Are Powering Growth in the Neurogenetic Testing Market?
North America was the largest region in the neurogenetic testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurogenetic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16131

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.